AdipoLABs opens an office in Malaysia... Full-fledged entry into Southeast Asia

AdipoLABs supplied a high-frequency hyperthermia cancer treatment device, ‘Remission 1℃’ to Malaysian government hospital and held an office opening event.

CEO Han Sung-ho said “We will do our best to help mankind be free from any pain from disease and relish a true happy life”

AdipoLABs, a new leader of global high-frequency hyperthermia market, is entering Southeast Asia in earnest. AdipoLABs Healthcare (Co-CEOs Moses and Isaac) in Malaysia, a Malaysian cooperative partner of AdipoLABs Co., Ltd. (CEO Sung-Ho Han), which specializes in manufacturing and selling high-frequency hyperthermia therapy devices, recently expanded its office. A special ceremony to celebrate the supply of hyperthermia cancer treatment device 'Remission 1℃' was recently held in Petaling Jaya, Malaysia.

The event was attended by AdipoLABs’ CEO Han Sung-ho, Dr. Yoo Seung-mo from Chungnam Yesan Myongji Hospital , KOTRA’s marketing manager of Malaysia, Lee Kyung-nam, AdipoLABs Healthcare CEOs, Moses and Isaac, former Malaysian Minister of Health and Welfare, Tan Sri Dr. Suleiman Mohamed, Malaysian cardiologist Dr. Lesli Lam along with 50 Malaysian medical staff, business-related workers, and 100 people related to the medical center.

Following the introduction of distinguished guests and congratulatory remarks by Sung-ho Han, CEO of Adipo Labs, Dr. Jawabi of Malaysia stepped up to deliver a presentation on hyperthermia therapy and congratulated the relocation of the office.

In particular, this event provided an opportunity for AdipoLABs and AdipoLABs Healthcare's flagship medical device, 'Remission 1℃', a high-frequency hyperthermia cancer treatment device, to treat cancer patients not only in Korea but also in Malaysia and several Southeast Asian countries. It was evaluated as a meaningful event that conveyed a message of hope to enormous number of cancer patients all around the world.

In an interview with a Malaysian broadcaster related to this event, CEO Han Sung-ho emphasized, "This will give us a substantial opportunity for a joint research between the Korean medical team and Malaysian medical team while striving to help all mankind around the world to escape from pain of disease and pursue a happy life."

Meanwhile, AdipoLABs has been cooperating with Malaysia since 2018 and obtained a permission from MDA (Malaysian Food and Drug Administration) in 2020 for 'Remission 1℃', a high-frequency hyperthermia cancer treatment device. It plans to expand supply to Southeast Asian countries including Malaysia.

link: 아디포랩스, 말레이시아 사무실 오픈…동남아 진출 본격화:후생신보 (whosaeng.com)